Clinical Trial Update: Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of a sublingual immunotherapy solution for birch pollen–induced allergic rhinoconjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Birch Pollen-induced Allergic Rhinoconjunctivitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• Birch pollen sublingual immunotherapy solution (birch pollen extract)

Snippet

Sponsor: Stallergenes Greer | Conditions: Hypersensitivity, Allergic Rhinitis | Phase 3 | Status: COMPLETED